Nextech & Kymera: A Mildly Interesting Adjustment

by

Nextech Invest, Ltd., in a filing that caused approximately zero disruption to the space-time continuum, disclosed a reduction in its holding of Kymera Therapeutics (KYMR 0.69%). The sum involved – 62,013 shares, translating to roughly $4.19 million based on the rather arbitrary measurement we call “quarterly average pricing” – is, in the grand scheme of things, statistically insignificant. (Although, if you were to stack $4.19 million in single dollar bills, it would reach a height of approximately 83.5 kilometers, which is, incidentally, almost exactly halfway to the Karman line – the internationally recognized boundary of space. A completely useless fact, naturally.)

  • Nextech divested a portion of its Kymera Therapeutics shares, valued at approximately $4.19 million.
  • Despite the sales, the overall position value increased by $2.41 million, a curious phenomenon attributable to both market forces and the simple act of moving pieces around.
  • This transaction represented a mere 0.4% of the fund’s 13F reportable assets under management (AUM). A rounding error, really.
  • As of December 31, 2025, Nextech held 278,896 shares of Kymera, valued at $21.70 million.
  • Kymera now represents 2.1% of AUM, demoting it from a key player to a…well, a perfectly respectable supporting character.

What Happened

According to the aforementioned filing, dated February 17, 2026, Nextech executed a trim of its Kymera holding in the fourth quarter. The estimated transaction value, calculated using the average closing price – a concept fraught with philosophical implications, when you really think about it – was $4.19 million. The quarter-end value of the position actually increased by $2.41 million, a result of the complex interplay between selling shares and the stock’s…enthusiasm.

What Else to Know

  • Nextech continues to engage in normal trading activities, subtly reshaping its portfolio like a cosmic sculptor. The Kymera stake has been trimmed to 2.1% of 13F AUM.
  • Top five holdings, as of the filing:
    • NASDAQ:RVMD: $605.43 million (58.5% of AUM)
    • NASDAQ:TYRA: $106.63 million (10.3% of AUM)
    • NASDAQ:TNGX: $64.38 million (6.2% of AUM)
    • NASDAQ:ORIC: $58.59 million (5.7% of AUM)
    • NASDAQ:RLAY: $39.77 million (3.8% of AUM)
  • As of February 17, 2026, Kymera Therapeutics shares were trading at $84.84, up a rather improbable 128.5% over the past year. This outperforms the S&P 500 by 118.13 percentage points – a statistic that, if you stare at it long enough, may begin to question the very fabric of reality.

Company Overview

Metric Value
Price (as of market close March 18, 2026) $84.84
Market Capitalization $6.41 billion
Revenue (TTM) $39.21 million
Net Income (TTM) ($311.35 million)

Company Snapshot

  • Kymera Therapeutics develops novel small molecule therapeutics that target and degrade disease-causing proteins. Essentially, they’re building tiny demolition crews for the microscopic world.
  • The company operates a research-driven biopharmaceutical model, advancing its proprietary clinical pipeline. (A pipeline, incidentally, is a remarkably inefficient method of transporting fluids. But it sounds impressive.)
  • Kymera serves healthcare providers, research institutions, and pharmaceutical partners focused on innovative treatments for serious diseases.

Kymera Therapeutics focuses on targeted protein degradation therapies for immunology and oncology, developing a diversified clinical pipeline. Their strategy centers on first-in-class therapies for diseases with high unmet medical need, leveraging a robust research platform. (Which is, presumably, very robust. We haven’t personally inspected it.)

What This Transaction Means for Investors

Nextech sold approximately 18% of its Kymera position in Q4 – a trim, not an exit. The remaining stake is still worth $21.70 million, and the position value actually grew during the quarter despite the sales, thanks to price appreciation. (A truly baffling situation, when you consider the laws of thermodynamics.)

Nextech runs a highly concentrated book – Revolution Medicines alone constitutes nearly 60% of reportable assets. This reveals something about their approach: when they have conviction, they commit fully. Kymera, at 2.1%, is a satellite position by comparison. (A perfectly respectable satellite, mind you.)

Kymera is a protein degradation play in immunology and oncology – a platform approach that’s attracting attention in biotech circles because it targets what traditional small molecules can’t touch. A fund like Nextech trimming at current levels is standard risk management – the stock is retesting peaks it hit in December 2020, December 2025, and again last month. Trimming like this isn’t a red flag, just part of the ride. Fools watching Kymera should focus on pipeline catalysts. The more useful signal here is that Nextech still holds the position at all. (Which, in the grand scheme of things, is rather encouraging.)

Read More

2026-03-19 18:45